Imran Jadoon’s Post

Catalent on Tuesday released its fiscal first-quarter 2025 earnings report, touting 4% growth in its net revenue and “continued confidence” from its clients, but falling short of the consensus estimate. The CDMO giant brought in $1.02 billion in fiscal Q1, whereas analysts had projected nearly $1.06 billion in total revenue. The miss was driven by the disappointing performance across both of its main business units—Catalent’s biologics division brought in $461 million in the quarter, a 3% increase from the same period last year, but below the consensus forecast of $484 million. Despite reporting 5% year-over-year growth for its pharma and consumer health franchise, Catalent’s Q1 net revenue of $563 million missed the analyst estimate of $574 million. #biotech #biopharma #pharma #CDMO

"Haleon said on Tuesday top shareholder Pfizer offloaded a roughly $3.9 billion stake in the consumer healthcare firm, bringing down its holding in the British company to 22.6%. Pfizer previously held a 32% stake, followed by second-largest shareholder GSK which has a 4.2% holding. WHY IT'S IMPORTANT This is Pfizer's first stake sale in Haleon since the company was spun off from GSK and listed in 2022 - three years after its formation by combing the pharma giants' consumer healthcare units. Pfizer said last year it planned to cut its ownership in a "slow and methodical" manner within months. Meanwhile, GSK, which initially held a 12.9% stake, has sold it down over the last year, with the last sale in January." #finance #equipmentfinance #equipmentleasing #financialservices #corporatefinance #pfizer #gsk #haleon #pharmaceuticals https://lnkd.in/eeDpTUu3

💉 𝐖𝐡𝐲 𝐝𝐢𝐝 𝐭𝐡𝐞 𝐬𝐭𝐞𝐫𝐢𝐥𝐞 𝐢𝐧𝐣𝐞𝐜𝐭𝐚𝐛𝐥𝐞𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐛𝐫𝐞𝐚𝐤 𝐮𝐩 𝐰𝐢𝐭𝐡 𝐭𝐡𝐞 𝐧𝐨𝐧-𝐬𝐭𝐞𝐫𝐢𝐥𝐞 𝐝𝐫𝐮𝐠𝐬?.... 𝐁𝐞𝐜𝐚𝐮𝐬𝐞 𝐢𝐭 𝐜𝐨𝐮𝐥𝐝𝐧’𝐭 𝐡𝐚𝐧𝐝𝐥𝐞 𝐭𝐡𝐞𝐢𝐫 𝐝𝐢𝐫𝐭𝐲 𝐡𝐚𝐛𝐢𝐭𝐬! Aterian Investment Partners in the big apple 🍎 have acquired Contract Pharmaceuticals Limited in Canada within the Sterile injectables market, I can imagine there will be further US expansion coming! #cdmo #acquisitions #marketgrowth

Pfizer Inc (NYSE:PFE, ETR:PFE) has confirmed it will sell a large chunk of its stake in Haleon PLC (LSE:HLN, NYSE:HLN), raising over £2 billion (US$2.55bn). Haleon, a former consumer health joint venture between GSK and Pfizer that was spun out in 2022, aims to but £315 million of the shares, it said. The sale of roughly 630 million Haleon shares, including American depositary shares is expected to reduce Pfizer's shareholding in Haleon from 32% to around 24%. Pfizer's remaining stake is expected to be subject to a 90-day lock-up. More at #Proactive #ProactiveInvestors http://ow.ly/KphK105mmE5

Exciting IPO Alert! Today's the last date to apply - Hurry Up! Get ready for a thrilling investment opportunity with the upcoming Emcure Pharmaceuticals Limited IPO! Remarks – Can apply for listing gains as well as long-term investment Incorporated in 1981, Emcure Pharmaceuticals Limited, an Indian pharmaceutical company, develops, manufactures, and globally markets a wide range of pharmaceutical products across several major therapeutic areas. Don't miss out on this exciting opportunity! ** The views shared on upcoming IPOs are for educational & informational purposes only and not a substitute for professional investment advice; always consult your financial advisor before making any Investment decisions. For investment guidance and more info, contact us at Money Compound! 📱 8447496480 📩 [email protected] #IPOAlert #EmcurePharma #InvestmentOpportunity #StockMarket #Pharmaceuticals #InvestNow #FinancialFreedom #LongTermInvestment #ListingGains #IndianPharma #Investor #MarketWatch #IPO2024 #InvestmentGoals #FinancialPlanning #WealthManagement #StockMarketNews #PharmaStocks #GlobalMarkets #MarketOpening #SmartInvesting #InvestmentStrategy #MarketGains #FinancialGrowth #InvestInFuture

Dear LinkedIn Community, I'm excited to share insights on Emcure Pharmaceuticals Limited's upcoming IPO scheduled to open on 3rd July and close on 5th July. This IPO presents a significant opportunity to invest in a company deeply rooted in the pharmaceutical sector. To Know more swipe through the carousel. Stay tuned for more updates and Happy Investing! I thank Equivaluesearch and Saumitra Mondal for guidance. #EmcureIPO #InvestmentOpportunity #PharmaceuticalSector #FinancialAnalysis #IPO #Growth #Investment

📊 Top Large Pharmas by 2024 Cash Available 👇 M&A activity in pharma has been slow in 2024, mirroring 2023, aside from Pfizer's $43B Seagen acquisition. Large pharmaceutical companies face urgent pressures from both the IRA and the looming loss of exclusivity on key drugs. LOE will erode revenues as generics enter the market, while the IRA squeezes pricing. 💡 10 drugs facing LOE issues within the next 9 years generated $125B in worldwide sales in 2023. M&A remains essential to fill pipelines and maintain growth. Heightened FTC scrutiny on large deals adds complexity, making it harder to execute transformative acquisitions. With over $170B in cash reserves, pharma giants are well-positioned to reignite M&A activity heading into late 2024 and 2025. 📊 Below a report of their cash & equivalents status as of the end of June 2024.

Day 3: Pfizer Merges with Warner-Lambert 🚀 M&A Spotlight Series: Landmark Healthcare Deals! 🚀 🌟 Deal of the Day: Pfizer Merges with Warner-Lambert 🌟 In 2000, Pfizer’s $90 billion merger with Warner-Lambert marked one of the largest deals in pharmaceutical history. Here’s why it was significant: 💊 Blockbuster Drug: The merger gave Pfizer full control over Lipitor, the world’s best-selling cholesterol-lowering drug, significantly boosting its revenue. 🔬 R&D Synergies: Combining research and development capabilities enhanced Pfizer’s innovation pipeline and accelerated the development of new drugs. 🌐 Market Leadership: The merger solidified Pfizer’s position as a global leader in the pharmaceutical industry. 📊 Financial Strength: The deal brought substantial financial benefits, including increased cash flow and stronger balance sheets. Key Takeaway: Strategic mergers in the pharmaceutical industry can drive growth through blockbuster drugs and R&D synergies. 🔍 What’s Next?: Tomorrow, we’ll explore a groundbreaking deal in the retail industry that revolutionized online shopping. #InvestmentBanking #MandA #Pharmaceuticals #Pfizer #WarnerLambert #MergersAndAcquisitions #CareerGrowth

Just because a business does not make any money, does not mean that the stock will go down. For example, Corbus... For daily news and analysis subscribe to the https://lnkd.in/gnuy4bKp newsletter. #Biopharma #Pharmaceuticals #Healthcare

Strategic Consolidation: SUN PHARMA – Taro Pharmaceuticals Merger, Bolstering Global Presence #StrategicMerger The #shareholders of Taro have greenlit the merger with Sun Pharma, signaling a strategic consolidation in the #pharmaceutical industry. #GlobalExpansion This merger, subject to closing conditions, is poised to enhance patient care and customer service on a global scale, leveraging Sun Pharma's extensive resources. #SynergisticGrowth Taro's 15-year collaboration with Sun Pharma culminates in a merger that promises competitive edge and innovation in product offerings and market presence. #PrivatizationMove Post-merger, Taro will transition into a privately held entity under Sun Pharma, with plans to withdraw from the NYSE, streamlining operations and governance. SUN PHARMA Taro Pharmaceuticals For more Information: https://lnkd.in/gU8DPpdT https://lnkd.in/griGxgUV -PP Prathyusha Pitta. Ph.D., MBA #PPInsights #SunPharma #Taro #HealthcareInnovation #MarketLeadership #Pharmaceuticals #LIPostingChallengeIndia #EY #EYParthenon #consulting #pharma #womeninconsulting #consultants #businessadvisory #strategyconsulting #healthcare #pharmaceuticals #healthcareconsulting #businessstrategy #managementconsulting #womenleaders #womenempowerment #genderdiversity #professionalwomen #careerdevelopment #leadership #womeninbusiness #consultingfirm #businessconsulting #pharmaceuticalindustry